Payback Time For Lilly? Erbitux Follow-on Succeeds In Squamous Lung Cancer Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly’s necitumumab – gained through the company’s ImClone acquisition – demonstrates an overall survival benefit in the SQUIRE study against first-line metastatic squamous NSCLC. Pleasantly surprised by the outcome, some analysts start to expect blockbuster sales.
You may also be interested in...
Lilly's Necitumumab: FDA Panel To Weigh Modest Survival Benefit Against Thromboembolic Risks
Is benefit/risk profile in squamous non-small cell lung cancer impacted by Phase III results from trial in non-squamous population that was halted early due to safety issues?
Lilly Drug Shows Survival Benefit In NSCLC, Raising Its Prospects
Expectations for Eli Lilly’s ramucirumab were dampened after it failed in a Phase III trial in breast cancer patients, but enthusiasm for the drug has been reignited now that it demonstrated a survival benefit in one of oncology’s riskiest areas – lung cancer.
Lilly Drug Shows Survival Benefit In NSCLC, Raising Its Prospects
Expectations for Eli Lilly’s ramucirumab were dampened after it failed in a Phase III in breast cancer patients, but enthusiasm for the drug has been reignited now that it demonstrated a survival benefit in one of oncology’s riskiest areas – lung cancer.